Investor's Business Daily on MSN
Constellium, IBD stock of the day, forges bullish entry after 72% rally amid accelerating growth
Stock Of The Day: Constellium earnings and sales growth are accelerating amid strong aluminum prices and demand. Shares are setting up after a big rally.
A global meta-analysis finds that anemia affects 37% of patients with inflammatory bowel disease, highlighting gaps in ...
For decades, large portions of the human genome were labeled "junk DNA." New research from Western University and London ...
Spyre Therapeutics CEO Cameron Turtle talks about the search for an IBD treatment on this week's "The Readout LOUD." ...
Patients with IBD may experience increased serum levels of vitamin D with supplementation, but improvement in disease ...
MedPage Today on MSN
Hep B in blood transfusions; ultraprocessed foods and IBD; the microbiome and CRC
News and commentary from the world of gastroenterology and hepatology ...
MedPage Today on MSN
Incidence of Bowel Disease in Kids Nearly Quadrupled Over 40 Years
Danish study also showed more extensive disease at diagnosis, earlier onset with family hi ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients with IBD had an increased risk for venous ...
New ECCO dietary therapy guidelines for IBD clarify the role of enteral nutrition, Mediterranean diet, supplements, and RD ...
The Crown Heights Crohns and Colitis Support will feature a leading physician, Dr. Michael Dolinger, who has revolutionized IBD care.
In February 2026, Sanofi and Teva Pharmaceutical Industries reported positive long-term phase 2b extension results for duvakitug, showing sustained clinical and endoscopic efficacy over 44 weeks in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results